Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type
Aptose Biosciences Inc TSX:APS Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.94% 1.05 1.05 1.11 1.07 1.05 1.07 6,200 21:00:00

Aptose Gets FDA Fast-Track Designation for HM43239

04/05/2022 1:22pm

Dow Jones News

Aptose Biosciences (TSX:APS)
Historical Stock Chart

From Feb 2022 to Aug 2022

Click Here for more Aptose Biosciences Charts.

By Colin Kellaher


Aptose Biosciences Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to HM43239 for the treatment of patients with relapsed or refractory acute myeloid leukemia with FLT3 mutation.

The Toronto clinical-stage oncology company is currently conducting a Phase 1/2 study of HM43239 in patients with the cancer of the blood and bone marrow.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. The agency previously granted orphan-drug designation to HM43239 for treatment of acute myeloid leukemia in 2018.


Write to Colin Kellaher at


(END) Dow Jones Newswires

May 04, 2022 08:07 ET (12:07 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Aptose Biosciences Chart

1 Year Aptose Biosciences Chart

1 Month Aptose Biosciences Chart

1 Month Aptose Biosciences Chart
ADVFN Advertorial
Your Recent History
Aptose Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220815 00:29:13